Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Frontage Holdings Corp. ( (HK:1521) ) is now available.
Frontage Holdings Corporation announced that shareholders at its extraordinary general meeting on January 7, 2026, approved an ordinary resolution by poll related to a share transfer agreement involving its Shanghai laboratory subsidiary and counterparties Hangzhou Tigermed Consulting and Jiaxing Xinge Medical Consulting. With major shareholders Hangzhou Tigermed and Hongkong Tigermed abstaining in line with earlier guidance, the remaining eligible shareholders voted unanimously in favour of ratifying the share transfer agreement and authorising directors to implement related transactions, clearing a key procedural hurdle for the restructuring and enabling the company to proceed with the planned corporate arrangements that may refine its collaboration and ownership structure within the broader clinical research ecosystem.
The most recent analyst rating on (HK:1521) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Frontage Holdings Corp. stock, see the HK:1521 Stock Forecast page.
More about Frontage Holdings Corp.
Frontage Holdings Corporation is a Cayman Islands-incorporated company listed in Hong Kong that operates in the contract research and related pharmaceutical services space through entities such as Frontage Laboratories (Shanghai) Co., Ltd., working with partners like Hangzhou Tigermed Consulting and Jiaxing Xinge Medical Consulting in China’s healthcare and life sciences market.
Average Trading Volume: 282,262
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.1B
For a thorough assessment of 1521 stock, go to TipRanks’ Stock Analysis page.